This case study describes the successful use of ravulizumab in treating a 71-year-old woman with myasthenia gravis experiencing a myasthenic crisis. The patient initially presented with hypernasality and dysphagia; her medical history included untreated, complicated type 1 diabetes. The patient received several treatments approved in Japan for general myasthenia gravis, including immunoadsorption plasmapheresis, tacrolimus, intravenous immunoglobulin, and intravenous methylprednisolone.
View Article and Find Full Text PDFMyasthenia gravis (MG) patients often require long-term glucocorticoid therapy, which may affect bone health. This study aimed to assess long-term changes in bone mineral density (BMD), evaluate osteoporotic fracture incidence, and examine the relationship between MG-specific factors and bone health outcomes over a 10-year period. This single-center, prospective cohort study included 28 MG patients.
View Article and Find Full Text PDFWe isolated for the first time in Asia, alongside , from blood culture specimens in a case of complicated urinary tract infection with sepsis. In our case, took 96 hours to form colonies under anaerobic culture and showed sensitivity to ceftriaxone, administered for the urinary tract infection. The pathogenicity and clinical significance of , as well as its impact on the host when coinfected with other pathogens, require further analysis through the accumulation of cases.
View Article and Find Full Text PDF